Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Progressive Decline in Gray and White Matter Integrity in de novo Parkinson's Disease: An Analysis of Longitudinal Parkinson Progression Markers Initiative Diffusion Tensor Imaging Data.

Taylor KI, Sambataro F, Boess F, Bertolino A, Dukart J.

Front Aging Neurosci. 2018 Oct 8;10:318. doi: 10.3389/fnagi.2018.00318. eCollection 2018.

2.

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.

Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG.

JAMA Neurol. 2018 Oct 1;75(10):1206-1214. doi: 10.1001/jamaneurol.2018.1487.

3.

Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects.

Wong DF, Comley RA, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, Vozzi C, Boess F, Oh E, Lyketsos CG, Honer M, Gobbi L, Klein G, George N, Gapasin L, Kitzmiller K, Roberts J, Sevigny J, Nandi A, Brasic J, Mishra C, Thambisetty M, Mogekar A, Mathur A, Albert M, Dannals RF, Borroni E.

J Nucl Med. 2018 Dec;59(12):1869-1876. doi: 10.2967/jnumed.118.209916. Epub 2018 May 4. Erratum in: J Nucl Med. 2019 Jan;60(1):141.

4.

Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.

Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, Schjodt-Eriksen J, Cheng WY, Fernandez-Garcia I, Siebourg-Polster J, Jin L, Soto J, Verselis L, Boess F, Koller M, Grundman M, Monsch AU, Postuma RB, Ghosh A, Kremer T, Czech C, Gossens C, Lindemann M.

Mov Disord. 2018 Aug;33(8):1287-1297. doi: 10.1002/mds.27376. Epub 2018 Apr 27.

5.

Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor.

Kratochwil NA, Triyatni M, Mueller MB, Klammers F, Leonard B, Turley D, Schmaler J, Ekiciler A, Molitor B, Walter I, Gonsard PA, Tournillac CA, Durrwell A, Marschmann M, Jones R, Ullah M, Boess F, Ottaviani G, Jin Y, Parrott NJ, Fowler S.

J Pharmacol Exp Ther. 2018 May;365(2):237-248. doi: 10.1124/jpet.117.245712. Epub 2018 Feb 16.

PMID:
29453199
6.

Erratum to: Pathway reporter genes define molecular phenotypes of human cells.

Zhang JD, Küng E, Boess F, Certa U, Ebeling M.

BMC Genomics. 2017 May 2;18(1):337. doi: 10.1186/s12864-017-3730-6. No abstract available.

7.

Use of early phenotypic in vivo markers to assess human relevance of an unusual rodent non-genotoxic carcinogen in vitro.

Boess F, Lenz B, Funk J, Niederhauser U, Bassett S, Zhang JD, Singer T, Roth AB.

Toxicology. 2017 Mar 15;379:48-61. doi: 10.1016/j.tox.2017.01.018. Epub 2017 Feb 5.

PMID:
28174063
8.

Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail.

Berger B, Donzelli M, Maseneni S, Boess F, Roth A, Krähenbühl S, Haschke M.

Front Pharmacol. 2016 Nov 21;7:443. eCollection 2016.

9.

Establishment of a Predictive In Vitro Assay for Assessment of the Hepatotoxic Potential of Oligonucleotide Drugs.

Sewing S, Boess F, Moisan A, Bertinetti-Lapatki C, Minz T, Hedtjaern M, Tessier Y, Schuler F, Singer T, Roth AB.

PLoS One. 2016 Jul 21;11(7):e0159431. doi: 10.1371/journal.pone.0159431. eCollection 2016.

10.

Biomarkers of Flutamide-Bioactivation and Oxidative Stress In Vitro and In Vivo.

Teppner M, Boess F, Ernst B, Pähler A.

Drug Metab Dispos. 2016 Apr;44(4):560-9. doi: 10.1124/dmd.115.066522. Epub 2016 Jan 27.

PMID:
26817949
11.

Minimizing DILI risk in drug discovery - A screening tool for drug candidates.

Schadt S, Simon S, Kustermann S, Boess F, McGinnis C, Brink A, Lieven R, Fowler S, Youdim K, Ullah M, Marschmann M, Zihlmann C, Siegrist YM, Cascais AC, Di Lenarda E, Durr E, Schaub N, Ang X, Starke V, Singer T, Alvarez-Sanchez R, Roth AB, Schuler F, Funk C.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):429-37. doi: 10.1016/j.tiv.2015.09.019. Epub 2015 Sep 25.

PMID:
26407524
12.

Pathway reporter genes define molecular phenotypes of human cells.

Zhang JD, Küng E, Boess F, Certa U, Ebeling M.

BMC Genomics. 2015 Apr 24;16:342. doi: 10.1186/s12864-015-1532-2. Erratum in: BMC Genomics. 2017 May 2;18(1):337.

13.

Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study.

Buvat J, Hatzichristou D, Boess FG, Büttner H, Gehchan N, Henneges C, Porst H.

Int J Clin Pract. 2014 Sep;68(9):1087-99. doi: 10.1111/ijcp.12449. Epub 2014 Aug 14.

PMID:
25123817
14.

Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice.

Ziegler D, Schneider E, Boess FG, Berggren L, Birklein F.

J Diabetes Complications. 2014 Sep-Oct;28(5):698-704. doi: 10.1016/j.jdiacomp.2014.04.004. Epub 2014 Apr 18.

PMID:
24862108
15.

Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study.

Hatzimouratidis K, Buvat J, Büttner H, Vendeira PA, Moncada I, Boehmer M, Henneges C, Boess FG.

Int J Impot Res. 2014 Nov-Dec;26(6):223-9. doi: 10.1038/ijir.2014.15. Epub 2014 May 1.

PMID:
24784894
16.

Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study.

Happich M, Schneider E, Boess FG, Wilhelm S, Schacht A, Birklein F, Ziegler D.

Clin J Pain. 2014 Oct;30(10):875-85. doi: 10.1097/AJP.0000000000000057.

PMID:
24296910
17.

Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.

Porst H, Gacci M, Büttner H, Henneges C, Boess F.

Eur Urol. 2014 Feb;65(2):455-64. doi: 10.1016/j.eururo.2013.09.037. Epub 2013 Oct 2.

PMID:
24119319
18.

Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.

Buvat J, Büttner H, Hatzimouratidis K, Vendeira PA, Moncada I, Boehmer M, Henneges C, Boess FG.

J Sex Med. 2013 Jun;10(6):1592-602. doi: 10.1111/jsm.12130. Epub 2013 Apr 2.

PMID:
23551622
19.

Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man.

Boess F, Bertinetti-Lapatki C, Zoffmann S, George C, Pfister T, Roth A, Lee SM, Thasler WE, Singer T, Suter L.

J Mol Endocrinol. 2013 Apr 12;50(3):325-36. doi: 10.1530/JME-12-0186. Print 2013 Jun.

PMID:
23463748
20.

A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity.

Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer T, Naughton B, Roth A.

Toxicol Appl Pharmacol. 2013 Apr 1;268(1):1-16. doi: 10.1016/j.taap.2013.01.012. Epub 2013 Jan 23.

PMID:
23352505
21.

Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Boess FG, de Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, König G.

Psychopharmacology (Berl). 2013 May;227(1):1-17. doi: 10.1007/s00213-012-2933-4. Epub 2012 Dec 16.

PMID:
23241647
22.

A label-free, impedance-based real time assay to identify drug-induced toxicities and differentiate cytostatic from cytotoxic effects.

Kustermann S, Boess F, Buness A, Schmitz M, Watzele M, Weiser T, Singer T, Suter L, Roth A.

Toxicol In Vitro. 2013 Aug;27(5):1589-95. doi: 10.1016/j.tiv.2012.08.019. Epub 2012 Aug 28.

PMID:
22954529
23.

Tolerability aspects in duloxetine-treated patients with depression: Should one use a lower starting dose in clinical practice?

Wilhelm S, Boess FG, Hegerl U, Mergl R, Linden M, Schacht A, Schneider E.

Expert Opin Drug Saf. 2012 Sep;11(5):699-711. doi: 10.1517/14740338.2012.699521. Epub 2012 Jun 20.

PMID:
22712514
24.

EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.

Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, König G.

Neuropharmacology. 2012 Feb;62(2):1099-110. doi: 10.1016/j.neuropharm.2011.10.024. Epub 2011 Nov 10.

PMID:
22085888
25.

Gene expression-based in vivo and in vitro prediction of liver toxicity allows compound selection at an early stage of drug development.

Roth A, Boess F, Landes C, Steiner G, Freichel C, Plancher JM, Raab S, de Vera Mudry C, Weiser T, Suter L.

J Biochem Mol Toxicol. 2011 May-Jun;25(3):183-94. doi: 10.1002/jbt.20375. Epub 2010 Nov 12.

PMID:
21671310
26.

Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

Lakics V, Karran EH, Boess FG.

Neuropharmacology. 2010 Nov;59(6):367-74. doi: 10.1016/j.neuropharm.2010.05.004. Epub 2010 May 21. Erratum in: Neuropharmacology. 2013 Apr;67:532.

PMID:
20493887
27.

Use of behavioural and long-term potentiation models in the development of memory-improving drugs.

Blokland A, Boess F.

Expert Opin Drug Discov. 2008 Sep;3(9):1067-80. doi: 10.1517/17460441.3.9.1067.

PMID:
23506180
28.

An in vitro study on 5-HT6 receptor antagonist induced hepatotoxicity based on biochemical assays and toxicogenomics.

Boess F, Durr E, Schaub N, Haiker M, Albertini S, Suter L.

Toxicol In Vitro. 2007 Oct;21(7):1276-86. Epub 2007 Apr 5.

PMID:
17513084
29.

The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.

Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, Koenig G.

J Pharmacol Exp Ther. 2007 May;321(2):716-25. Epub 2007 Feb 16.

PMID:
17308038
30.

Gene expression analysis of the hepatotoxicant methapyrilene in primary rat hepatocytes: an interlaboratory study.

Beekman JM, Boess F, Hildebrand H, Kalkuhl A, Suter L.

Environ Health Perspect. 2006 Jan;114(1):92-9.

31.

Assessment of hepatotoxic liabilities by transcript profiling.

Ruepp S, Boess F, Suter L, de Vera MC, Steiner G, Steele T, Weiser T, Albertini S.

Toxicol Appl Pharmacol. 2005 Sep 1;207(2 Suppl):161-70. Review.

PMID:
15990132
32.

Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.

Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G.

Neuropharmacology. 2004 Dec;47(7):1081-92.

PMID:
15555642
33.

Discriminating different classes of toxicants by transcript profiling.

Steiner G, Suter L, Boess F, Gasser R, de Vera MC, Albertini S, Ruepp S.

Environ Health Perspect. 2004 Aug;112(12):1236-48.

34.

In vitro investigation on the impact of Solutol HS 15 on the uptake of colchicine into rat hepatocytes.

Bravo González RC, Boess F, Durr E, Schaub N, Bittner B.

Int J Pharm. 2004 Jul 26;279(1-2):27-31.

PMID:
15234791
35.

AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors.

Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R.

Psychopharmacology (Berl). 2004 Apr;172(4):375-83. Epub 2004 Jan 15.

PMID:
14727003
36.

In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam.

Bravo González RC, Huwyler J, Boess F, Walter I, Bittner B.

Biopharm Drug Dispos. 2004 Jan;25(1):37-49.

PMID:
14716751
37.

[INVITOX 2002: 12th International workshop on in vitro toxicology].

Boess F, Scholz G, Spielman H.

ALTEX. 2003;20(1):36-9. German. No abstract available.

PMID:
12674101
38.
39.

Modulation of gene and protein expression by carbon tetrachloride in the rat liver.

Fountoulakis M, de Vera MC, Crameri F, Boess F, Gasser R, Albertini S, Suter L.

Toxicol Appl Pharmacol. 2002 Aug 15;183(1):71-80.

PMID:
12217644
40.

Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes.

Heim M, Johnson J, Boess F, Bendik I, Weber P, Hunziker W, Fluhmann B.

FASEB J. 2002 May;16(7):718-20. Epub 2002 Mar 26.

PMID:
11923221
41.

Luminol as a probe to assess reactive oxygen species production from redox-cycling drugs in cultured hepatocytes.

Boess F, Boelsterli UA.

Toxicol Mech Methods. 2002;12(1):79-94. doi: 10.1080/15376510209167938.

PMID:
20597818
42.

Effects of cocaine and its oxidative metabolites on mitochondrial respiration and generation of reactive oxygen species.

Boess F, Ndikum-Moffor FM, Boelsterli UA, Roberts SM.

Biochem Pharmacol. 2000 Sep 1;60(5):615-23.

PMID:
10927019
43.

Importance of phenylalanine 107 in agonist recognition by the 5-hydroxytryptamine(3A) receptor.

Steward LJ, Boess FG, Steele JA, Liu D, Wong N, Martin IL.

Mol Pharmacol. 2000 Jun;57(6):1249-55.

PMID:
10825397
44.

Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats.

Bentley JC, Bourson A, Boess FG, Fone KC, Marsden CA, Petit N, Sleight AJ.

Br J Pharmacol. 1999 Apr;126(7):1537-42.

45.

Residues in transmembrane regions III and VI contribute to the 5-ht6 receptor ligand binding site.

Boess FG, Monsma FJ Jr, Bourson A, Zwingelstein C, Sleight AJ.

Ann N Y Acad Sci. 1998 Dec 15;861:242-3. No abstract available.

PMID:
9928266
46.

Comparison of native 5-HT3 receptors purified from various neuroblastoma-derived cell lines and bovine brain with recombinant 5-HT3-AL receptors purified after expression in HEK293 cells.

Boess FG, Creighton RM, Phipps BA, McKernan RM, Reid J, Martin IL.

Ann N Y Acad Sci. 1998 Dec 15;861:276-7. No abstract available.

PMID:
9928288
47.

The putative 5-ht6 receptor: localization and function.

Sleight AJ, Boess FG, Bös M, Bourson A.

Ann N Y Acad Sci. 1998 Dec 15;861:91-6. Review.

PMID:
9928244
48.

Involvement of 5-HT6 receptors in nigro-striatal function in rodents.

Bourson A, Boess FG, Bös M, Sleight AJ.

Br J Pharmacol. 1998 Dec;125(7):1562-6.

50.

The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum.

Boess FG, Riemer C, Bös M, Bentley J, Bourson A, Sleight AJ.

Mol Pharmacol. 1998 Sep;54(3):577-83.

PMID:
9730917

Supplemental Content

Support Center